Evidence map›Paper›PMID 30506268›Full record

ArticleTranslational stroke research2019

Preclinical Validation of the Therapeutic Potential of Glasgow Oxygen Level Dependent (GOLD) Technology: a Theranostic for Acute Stroke.

Graeme A Deuchar, Josie C van Kralingen, Lorraine M Work, Celestine Santosh, Keith W Muir, Chris McCabe, I Mhairi Macrae

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Translational stroke research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Graeme A DeucharAurum Biosciences Ltd, 20-23 Woodside Place, Glasgow, Scotland, G3 7QL, UK. gdeuchar@aurumbiosciences.com.
Josie C van KralingenInstitute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
Lorraine M WorkInstitute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
Celestine SantoshAurum Biosciences Ltd, 20-23 Woodside Place, Glasgow, Scotland, G3 7QL, UK.
Keith W MuirInstitute of Neuroscience & Psychology, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
Chris McCabeInstitute of Neuroscience & Psychology, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
I Mhairi MacraeInstitute of Neuroscience & Psychology, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, Glasgow, Scotland, UK.
University of Glasgow · GBAurum Biosciences (United Kingdom) · GBQueen Elizabeth University Hospital · GB

Funding

Chief Scientist Office ETM/146Chief Scientist Office, NHS Scotland ETM/146
6 · The paper itself

Abstract

In acute stroke patients, penumbral tissue is non-functioning but potentially salvageable within a time window of variable duration and represents target tissue for rescue. Reperfusion by thrombolysis and/or thrombectomy can rescue penumbra and improve stroke outcomes, but these treatments are currently available to a minority of patients. In addition to the utility of Glasgow Oxygen Level Dependent (GOLD) as an MRI contrast capable of detecting penumbra, its constituent perfluorocarbon (PFC) oxygen carrier, combined with normobaric hyperoxia, also represents a potential acute stroke treatment through improved oxygen delivery to penumbra. Preclinical studies were designed to test the efficacy of an intravenous oxygen carrier, the perfluorocarbon emulsion Oxycyte® (O-PFC), combined with normobaric hyperoxia (50% O

Indexed as

AnimalsBrain IschemiaCell Line, TumorFluorocarbonsMaleNeuronsOxygenOxygen Inhalation TherapyRats, Sprague-DawleyRats, WistarStrokeTheranostic NanomedicineFluorocarbonsOxygenperfluoro(t-butylcyclohexane)HyperoxiaMRIOxycyte (O-PFC)Oxygen carrierPenumbraPerfluorocarbonStroke

Identifiers

PMID30506268
PMCPMC6733820
OpenAlexW2900775110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.